Treating Adult Patients with Growth Hormone Deficiency: Diagnostic Tools and New Treatment Options for Optimal HealthPremiere Date: Wednesday, May 18, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, May 18, 2023
Note: Credit Is No Longer Available
|Kevin C.J. Yuen, MD, FRCP (UK), FACE (Moderator)
Medical Director of Barrow Pituitary Center
Barrow Neurological Institute
Professor of Medicine
University of Arizona College of Medicine and Creighton School of Medicine
|Mark E. Molitch, MD
Division of Endocrinology, Metabolism and Molecular Medicine
Northwestern University Feinberg School of Medicine
|Julie M. Silverstein, MD
Medical Director Pituitary Center
Associate Professor of Medicine and Neurological Surgery
Division of Endocrinology, Metabolism and Lipid Research
Washington University School of Medicine
St. Louis, MO
The clinical management of adult growth hormone deficiency (GHD) comprises caring for patients who are transitioning from pediatric to adult services, as well as patients with adult-onset (AO) GHD. There are unique challenges and opportunities in both scenarios, including who and when to test, which diagnostic tests to use, consideration of current and emerging treatment strategies, and improving patient adherence to therapies. The “art of medicine” and shared decision-making play important roles in GHD – as both medical and psychological factors need to be addressed to optimize outcomes.
In this OnDemand CMEO symposium, three experts in GHD follow the patient journeys of a young adult transitioning from pediatric care and a 50-year-old patient with AO-GHD. Clinical application of guidelines, a review of key study results, and the role of long-acting growth hormone preparations will be discussed.
At the end of this CE activity, participants should be able to:
- Incorporate evidence-based diagnostic testing to achieve a prompt and accurate diagnosis in individuals with GHD.
- Outline the clinical challenges associated with the management of GHD.
- Evaluate the current and emerging treatment strategies for the management of GHD.
Supported by an educational grant from Novo Nordisk, Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in endocrinology.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Yuen reports the following financial relationships:
Advisory Board: Amryt Pharma; Ascendis Pharma Group; Corcept; Crinetics; Ipsen Pharma; Novo Nordisk; Rani Therapeutics; Recordati; and Strongbridge Biopharma
Research Support: Grants paid to Barrow Neurological Institute: Amryt Pharma; Ascendis Pharma Group; Corcept; and Novartis
Dr. Molitch reports the following financial relationships:
Advisory Board: Strongbridge Biopharma
Consultant: Amryt Pharma and Corcept
Dr. Silverstein reports the following financial relationships:
Advisory Board: Chiasma, Inc.; Recordati S.p.A.; and Strongbridge Biopharma plc
The following peer reviewer and CME Outfitters staff report no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).